Fillon, Mike <br/><br/>
Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.  [electronic resource] 

 -  CA: a cancer journal for clinicians  05 2018 
 - 178-179 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>1542-4863 
<br/><br/><label>Standard No.: </label>10.3322/caac.21423  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Carcinoma, Non-Small-Cell Lung<br/>Docetaxel<br/>Humans<br/>Lung Neoplasms